<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03974113</url>
  </required_header>
  <id_info>
    <org_study_id>EFC15467</org_study_id>
    <secondary_id>2019-000679-18</secondary_id>
    <secondary_id>U1111-1223-4368</secondary_id>
    <nct_id>NCT03974113</nct_id>
  </id_info>
  <brief_title>Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B</brief_title>
  <acronym>ATLAS-PEDS</acronym>
  <official_title>ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      - To confirm appropriate dose levels of fitusiran when administered to male pediatric&#xD;
      participants (ages 1 to &lt;12 years of age) with severe hemophilia A or B&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
        -  To characterize the safety and tolerability&#xD;
&#xD;
        -  To determine fitusiran plasma concentrations at selected time points&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant is approximately 160 weeks, including a 12-week fitusiran&#xD;
      efficacy period&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2020</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">August 9, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma antithrombin (AT) activity levels</measure>
    <time_frame>Day 1 to end of efficacy period (up to Day 85 or Day 197)</time_frame>
    <description>Percent change in plasma antithrombin (AT) activity levels at the end of the efficacy period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants reported with adverse events</measure>
    <time_frame>160 weeks</time_frame>
    <description>Number of participants reported with treatment-emergent adverse events (TEAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fitusiran plasma concentrations</measure>
    <time_frame>Day 1 and Day 85</time_frame>
    <description>Plasma samples will be collected for measurement of plasma concentrations of fitusiran at specific time points postdose on Day 1 and predose on Day 85</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hemophilia</condition>
  <arm_group>
    <arm_group_label>Fitusiran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a selected dose of fitusiran on regular intervals, as per study protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fitusiran</intervention_name>
    <description>Pharmaceutical form:Solution for injection Route of administration: Subcutaneous</description>
    <arm_group_label>Fitusiran</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Male, aged 1 to &lt;12 years at the time of enrollment&#xD;
&#xD;
          -  Severe hemophilia A or B (Factor VIII (FVIII) &lt;1% or Factor IX (FIX) ≤2%)&#xD;
&#xD;
          -  Participants must have inhibitory antibodies to FVIII or FIX and must meet one of the&#xD;
             following Nijmegen-modified Bethesda assay results criteria:&#xD;
&#xD;
               -  Inhibitor titer of ≥0.6 BU/mL at screening, OR&#xD;
&#xD;
               -  Inhibitor titer of &lt;0.6 BU/mL at screening with medical record evidence of 2&#xD;
                  consecutive titers ≥0.6 BU/mL, OR&#xD;
&#xD;
               -  Inhibitor titer of &lt;0.6 BU/mL at screening with medical record evidence of 1&#xD;
                  inhibitor titer ≥0.6 BU/mL and a history of anamnestic response or severe&#xD;
                  allergic reaction (anaphylaxis or nephrotic syndrome)&#xD;
&#xD;
          -  Adequate peripheral venous access, as determined by the Investigator, to allow the&#xD;
             blood draws required by the study protocol&#xD;
&#xD;
          -  Weight requirements at the time of enrollment: 8 to &lt;45 kg&#xD;
&#xD;
          -  Willing and able to comply with the study requirements and to provide signed written&#xD;
             informed consent obtained from parent(s)/legal guardian (hereinafter the &quot;parent&quot;) and&#xD;
             written or oral assent obtained from participant, per local and national requirements&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Known co-existing bleeding disorders other than hemophilia A or B&#xD;
&#xD;
          -  Antithrombin (AT) activity &lt;60% at Screening&#xD;
&#xD;
          -  Co-existing thrombophilic disorder&#xD;
&#xD;
          -  Clinically significant liver disease&#xD;
&#xD;
          -  Active Hepatitis C virus infection&#xD;
&#xD;
          -  Acute or chronic Hepatitis B virus infection&#xD;
&#xD;
          -  Acute Hepatitis A or hepatitis E infection&#xD;
&#xD;
          -  HIV positive with a CD4 count of &lt;400 cells/μL&#xD;
&#xD;
          -  History of arterial or venous thromboembolism, unrelated to an indwelling venous&#xD;
             access&#xD;
&#xD;
          -  Inadequate renal function&#xD;
&#xD;
          -  History of multiple drug allergies or history of allergic reaction to an&#xD;
             oligonucleotide or N-Acetylgalactosamine (GalNAc)&#xD;
&#xD;
          -  Participants with central or peripheral indwelling catheters, with history of venous&#xD;
             access complications leading to hospitalization and/or systemic anticoagulation&#xD;
             therapy&#xD;
&#xD;
          -  History of intolerance to subcutaneous (SC) injection(s)&#xD;
&#xD;
          -  The use of emicizumab (Hemlibra®) within 6 months prior to screening&#xD;
&#xD;
          -  Any other conditions or comorbidities that would make the patient unsuitable for&#xD;
             enrollment or could interfere with participation in or completion of the study, per&#xD;
             Investigator judgment&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>Option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 8400002</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400010</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400008</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400007</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400006</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1240001</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3560001</name>
      <address>
        <city>Pune-411011</city>
        <zip>411 011</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3560004</name>
      <address>
        <city>Vellore</city>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800002</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3800001</name>
      <address>
        <city>Milano</city>
        <zip>20121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240001</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7240002</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920003</name>
      <address>
        <city>Bornova</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920002</name>
      <address>
        <city>Fatih</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7920001</name>
      <address>
        <city>Seyhan</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>India</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 3, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

